Phase 2 Lung Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been diagnosed with non-small cell lung cancer (a type of lung cancer), confirmed through a lab test of tissue or cell samples.
• People whose cancer is at an advanced stage (stage IIIB, IIIC, or IV), or whose cancer has come back and cannot be treated with curative treatments such as chemotherapy combined with radiation.
• People who have not yet received any treatment for their cancer in its advanced or returned form. Prior treatment given before or after surgery, completed more than 6 months before joining the trial, is acceptable.
• People aged 70 or older, or people of any age who meet the medical definition of being "frail" (confirm with trial site).
• People whose cancer does not have certain genetic changes (called driver mutations) for which the FDA has approved specific targeted treatments. Note: for a type called squamous cell lung cancer, this genetic testing is optional.
• People whose cancer has a PD-L1 score (a marker measured on tumour cells) of less than 50%.
• People with a general health and activity level rated between 0 and 3 on a standard medical scale (ranging from fully active to capable of limited self-care).
• People whose cancer can be measured on scans according to standard medical guidelines (RECIST 1.1).
• People whose blood test results meet minimum levels for white blood cells, platelets, haemoglobin, liver function, and kidney function as required by the trial.
• People who are willing and able to understand and sign a written consent form.

Who may not be able to join:

• People whose life expectancy is estimated to be less than 3 months at the time of joining.
• People who have an active autoimmune disease (where the immune system attacks the body) that has needed ongoing medical treatment within the past 2 years.
• People who have been diagnosed with interstitial lung disease (a condition causing scarring of lung tissue).
• People whose kidneys are not filtering blood well enough, based on a measurement called creatinine clearance being below a certain level.
• People who have active, untreated symptoms caused by cancer that has spread to the brain or the lining around the brain. People whose brain involvement has been treated or causes no symptoms may still be considered eligible.
• People who need to take immune-suppressing medications on an ongoing basis, including steroids — with some exceptions allowed, such as: low-dose steroids (equivalent to 10 mg or less of prednisone daily), short courses of steroids that are fully stopped before joining, inhaled, nasal, or skin-applied steroids, or a reducing course of a steroid called dexamethasone used to treat brain-related swelling.

Important: Always verify eligibility with the trial site directly before applying.